All In Biotech

Drug Trial Radar · NCT03507790

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Oct 10, 2018

Primary completion

May 29, 2024

Study completion May 29, 2024

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
Collaborators
National Institute on Aging (NIA)
First posted
Apr 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Conditions

  • Mild to Moderate Alzheimer's Disease

Interventions

  • CT1812Drug

    Active Study Drug

  • PlaceboDrug

    Non-active study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 210 Days
  2. Number of Study Participants With at Least One Treatment Emergent Adverse Events (TEAs) and Serious Adverse Events (SAEs).Time frame: Up to 210 Days

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • 21st Century Neurology/ Xenoscience Inc.

    Phoenix, Arizona

  • Imaging Endpoints

    Scottsdale, Arizona

  • Ki Health Partners, LLC dba New England Institute for Clinical Research

    Stamford, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • Charter Research

    Lady Lake, Florida

  • ClinCloud, LLC

    Maitland, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • Compass Research LLC- Bioclinica Research

    The Villages, Florida

  • ClinCloud

    Viera, Florida

  • Alzheimer's Memory Center

    Charlotte, North Carolina

  • The Ohio State University - Wexner

    Columbus, Ohio

  • Neuro Behavirol Clinical Research C

    North Canton, Ohio

  • St Vincent's Hospital Sydney

    Ivanhoe, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Melbourne Health

    Parkville, Victoria, Australia

  • Australian Alzheimer's Research Foundation

    Nedlands, Western Australia, Australia

  • Neuro Health Centrum ltd

    Brno, Czechia

  • NeuropsychiatrieHK S.R.O

    Hradec Králové, Czechia

  • A-Shine S.R.O

    Pilsen, Czechia

  • Clintrial S.R.O

    Prague, Czechia

  • Neuropsychiatrie s.r.o.

    Prague, Czechia

  • Forbeli S.R.O

    Prague, Czechia

  • INEP

    Prague, Czechia

  • Vestra Clinics

    Rychnov nad Kněžnou, Czechia

  • Brain Research Den Bosch

    's-Hertogenbosch, Netherlands

  • Brain Research Center Amsterdam

    Amsterdam, Netherlands

  • Brain Research Center Zwolle

    Zwolle, Netherlands

  • Fundación ACE

    Barcelona, Spain

  • Hospital Clinico Universitario Virgen De La Arrixaca

    El Palmar, Spain

  • Centro de Salud San Juan

    Salamanca, Spain

  • Hospital Victoria EUGENIA. Unidad de Neurociencias.

    Seville, Spain

  • Fundación Neuropolis - Hospital Viamed Montecanal

    Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.